Dolasetron
Anzemet (dolasetron) is a small molecule pharmaceutical. Dolasetron was first approved as Anzemet on 1997-09-11. It is used to treat postoperative nausea and vomiting in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Anzemet
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dolasetron mesylate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ANZEMET | Validus Pharmaceuticals | N-020623 RX | 1997-09-11 | 1 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| anzemet | New Drug Application | 2019-01-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| postoperative nausea and vomiting | EFO_0004888 | D020250 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J1260 | Injection, dolasetron mesylate, 10 mg |
| Q0180 | Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen |
| S0174 | Dolasetron mesylate, oral 50 mg (for circumstances falling under the medicare statute, use q0180) |
Clinical
Clinical Trials
76 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | 2 | 2 | 2 | 4 | 5 | 14 |
| Cardiogenic shock | D012770 | R57.0 | 1 | 2 | 2 | 2 | 1 | 7 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | 1 | 1 | 1 | 1 | 4 |
| Sepsis | D018805 | A41.9 | — | 1 | 2 | 1 | 1 | 4 | |
| Hypotension | D007022 | EFO_0005251 | I95 | — | — | — | 1 | 1 | 2 |
| Low cardiac output | D002303 | — | — | 1 | 1 | — | 2 | ||
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | 1 | — | 1 | |
| Pulmonary edema | D011654 | EFO_1001134 | J81 | — | — | — | 1 | — | 1 |
| Mitral valve stenosis | D008946 | EFO_0007372 | — | — | — | 1 | — | 1 | |
| Head and neck neoplasms | D006258 | — | — | — | 1 | — | 1 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Septic shock | D012772 | A48.3 | — | 3 | 2 | — | 2 | 5 | |
| Coronary disease | D003327 | — | 1 | 3 | — | 1 | 5 | ||
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | 1 | 2 | — | 1 | 4 |
| Left ventricular dysfunction | D018487 | — | — | 1 | — | 2 | 3 | ||
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 2 | — | 1 | 3 |
| Cardio-renal syndrome | D059347 | — | 1 | 1 | — | — | 2 | ||
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | 1 | — | — | 1 |
| Tetralogy of fallot | D013771 | Q21.3 | — | — | 1 | — | — | 1 | |
| Infections | D007239 | EFO_0000544 | — | 1 | 1 | — | — | 1 | |
| Angina pectoris | D000787 | EFO_0003913 | I20 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Shock | D012769 | R57.1 | 1 | 1 | — | — | 1 | 2 | |
| Acute lung injury | D055371 | EFO_0004610 | — | 1 | — | — | — | 1 | |
| Dilated cardiomyopathy | D002311 | EFO_0000407 | I42.0 | 1 | 1 | — | — | — | 1 |
| Traumatic brain injuries | D000070642 | S06 | — | 1 | — | — | — | 1 | |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | — | — | — | 1 |
| Heart transplantation | D016027 | EFO_0010673 | — | 1 | — | — | — | 1 | |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | I25.1 | 1 | — | — | — | 2 | 3 | |
| Drug-related side effects and adverse reactions | D064420 | T88.7 | 1 | — | — | — | — | 1 | |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | 1 | — | — | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | — | 3 | 3 |
| Aortic valve stenosis | D001024 | EFO_0000266 | Q25.1 | — | — | — | — | 3 | 3 |
| Right ventricular dysfunction | D018497 | — | — | — | — | 2 | 2 | ||
| Left ventricular hypertrophy | D017379 | EFO_0003896 | — | — | — | — | 1 | 1 | |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | — | — | — | 1 | 1 |
| Diabetes complications | D048909 | — | — | — | — | 1 | 1 | ||
| Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | — | — | — | — | 1 | 1 |
| Persian gulf syndrome | D018923 | EFO_0007430 | — | — | — | — | 1 | 1 | |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | — | 1 | 1 |
| Cardiac output | D002302 | — | — | — | — | 1 | 1 |
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DOLASETRON |
| INN | dolasetron |
| Description | Dolasetron (trade name Anzemet) is a serotonin 5-HT3 receptor antagonist used to treat nausea and vomiting following chemotherapy. Its main effect is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much antiemetic effect when symptoms are due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors.
|
| Classification | Small molecule |
| Drug class | serotonin 5-HT3 receptor antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O[C@@H]1C[C@@H]2C[C@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12 |
Identifiers
| PDB | — |
| CAS-ID | 115956-12-2 |
| RxCUI | 68091 |
| ChEMBL ID | CHEMBL2368925 |
| ChEBI ID | — |
| PubChem CID | 60654 |
| DrugBank | DB00757 |
| UNII ID | 82WI2L7Q6E (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 689 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,044 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more